Boulder, CO: Edoceo Devices
announces the signing
of a worldwide strategic and preferred distribution agreement for a simple,
rapid, and affordable Saliva based COVID-19 antigen test, A-Detect™, that
provides results in 17 minutes or less.
The test is approved for sale now in the European Union consisting of 28 countries and another 5 countries that accept the European Union CE Mark.
“We believe that over 213 million COVID-19 tests of all types have been carried out so far in 2020 in Europe, and the United States is currently testing approximately 1.5 to 2.2 million people per day for COVID-19,” says Rod Reum, CEO Edoceo Devices. “The Edmond J. Safra Center for Ethics at Harvard University published a report in April 2020 that suggests that up to 20 million tests per day are needed to help fully remobilize the economy. We have not come close to that and most areas still face lock downs and severe restrictions on businesses. We are delighted to have secured a substantial quantity of rapid antigen testing units with the potential to help people and business get back to a more normal life as soon as possible.”
The potential additional revenue from
commercializing A-Detect can also help speed development of the new generation
Edoceo V-Detect™ and B-Detect™ testing devices and
boost the rate of potential returns for early investors in our company.
Features and benefits of the A-Detect Rapid Saliva Coronavirus Test Kit include:
About Edoceo Devices: Edoceo Devices is an emerging med-tech & biotech American company focused on viral and bacterial testing technology for the aquaculture, veterinary, health care, food processing and home monitoring markets, led by Edoceo’s Chief Science Officer, Dr. Kenneth Reardon, in collaboration with scientists at Colorado State University.